NCT00245362已完成2 期
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
Cell Genesys2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2002年6月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Safety
研究概览
简要总结
To evaluate the safety and effectiveness of CG8020 and CG2505.
详细描述
To evaluate clinical and laboratory safety of CG 8020 and CG 2505 and to evaluate the efficacy of CG 8020 and CG 2505 as measured by clinical benefit response, progression-free survival, survival and CA 19-9 serum marker levels in chemotherapy naive or experienced patients with nonresectable or metastatic adenocarcinoma of the pancreas
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic or cytologic diagnosis of nonresectable or metastatic pancreatic adenocarcinoma
- •Chemotherapy naïve or chemotherapy experienced pancreatic cancer
排除标准
- •Prior cancer vaccines or gene therapy
- •History of clinically significant autoimmune disease (eg, systemic lupus erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis)
- •History of another malignancy in the past five years, except adequately treated non-melanomatous skin cancer or superficial bladder cancer or carcinoma-in-situ of the cervix, unless approved by the Medical Monitor
结局指标
主要结局
Safety
Efficacy measured by clinical benefit response
Progression-free survivial
Overall survival
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Multiple MyelomaNCT03989414Celgene424
已完成
2 期
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast CancerRecurrent Breast CancerStage IV Breast CancerMale Breast CancerNCT00068588National Cancer Institute (NCI)24
已完成
2 期
A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT02908100Genentech, Inc.260
撤回
2 期
Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder CancerHigh GradeNon Muscle InvasiveBladder CancerNCT02143804CG Oncology, Inc.
尚未招募
1 期
A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCLiver CancerHCCNCT06584071Biotheus Inc.140